Dynacure Announces First Patient Dosed in Phase 1 / 2 ‘UNITE-CNM’ Study of DYN101 for the Treatment of Myotubular and Centronuclear Myopathies (CNM)siteadmin2020-11-07T02:19:18-08:00March 5, 2020|
Dynacure to Present at 40th Annual Cowen Healthcare Conferencesiteadmin2020-11-07T02:20:55-08:00February 26, 2020|
Dynacure’s Chief Scientific Officer, Dr. Belinda Cowling, Receives Irène Joliot-Curie Prize for Women in Business and Technologysiteadmin2020-11-07T02:22:26-08:00November 27, 2019|
Dynacure Presents New Preclinical Results on Muscle Targeting with Antisense Oligonucleotides at the 24th Annual International Congress of the World Muscle Societysiteadmin2020-11-07T02:27:05-08:00October 2, 2019|
Dynacure Wins Ernst & Young’s Prix “Born Global” Awardsiteadmin2020-11-07T02:28:09-08:00September 18, 2019|
Dynacure to Present at Chardan’s 3rd Annual Genetic Medicines Conferencesiteadmin2020-11-07T02:29:21-08:00September 11, 2019|
Dynacure Appoints David Garrett as Chief Financial Officersiteadmin2020-11-07T02:30:36-08:00September 3, 2019|
Dynacure Receives Orphan Drug Designation from the US FDA for DYN101, an Antisense Medicine to Treat Rare Disease ‘Centronuclear Myopathies’siteadmin2020-11-07T02:31:59-08:00August 8, 2019|
Dynacure Receives Orphan Drug Designation in the EU for DYN101, an Antisense Medicine to Treat Rare Disease ‘Centronuclear Myopathies’siteadmin2020-11-07T02:33:31-08:00July 11, 2019|
Dynacure Announces Approval of Clinical Trial Application for DYN101, an Antisense Medicine to Treat Rare Disease ‘Centronuclear Myopathies’siteadmin2020-11-07T02:35:45-08:00April 30, 2019|
Community